These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 3718377)

  • 1. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy of ginger with various antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Mims ME
    Clin Res Pr Drug Regul Aff; 1988; 6(2):129-36. PubMed ID: 11538042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
    Wood CD; Stewart JJ; Wood MJ; Manno JE; Manno BR; Mims ME
    Aviat Space Environ Med; 1990 Feb; 61(2):157-61. PubMed ID: 2178599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human assay of antimotion sickness drugs.
    Graybiel A; Wood CD; Knepton J; Hoche JP; Perkins GF
    Aviat Space Environ Med; 1975 Sep; 46(9):1107-18. PubMed ID: 1100039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of vestibular training on motion sickness, nystagmus, and subjective vertical.
    Clément G; Deguine O; Bourg M; Pavy-LeTraon A
    J Vestib Res; 2007; 17(5-6):227-37. PubMed ID: 18626134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Habituation and motion sickness.
    Wood CD; Stewart JJ; Wood MJ; Struve FA; Straumanis JJ; Mims ME; Patrick GY
    J Clin Pharmacol; 1994 Jun; 34(6):628-34. PubMed ID: 8083394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological interventions for motion sickness: cardiovascular effects.
    Sunahara FA; Farewell J; Mintz L; Johnson WH
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A270-6. PubMed ID: 3499896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of anti-cholinergic and cholinergic drugs on habituation to motion in rats.
    Morita M; Takeda N; Hasegawa S; Yamatodani A; Wada H; Sakai S; Kubo T; Matsunaga T
    Acta Otolaryngol; 1990; 110(3-4):196-202. PubMed ID: 2239207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motion sickness in cats: a symptom rating scale used in laboratory and flight tests.
    Suri KB; Crampton GH; Daunton NG
    Aviat Space Environ Med; 1979 Jun; 50(6):614-8. PubMed ID: 475712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of some effects of three antimotion sickness drugs on nystagmic responses to angular accelerations and to optokinetic stimuli.
    Collins WE; Schroeder DJ; Elam GW
    Aviat Space Environ Med; 1982 Dec; 53(12):1182-9. PubMed ID: 7159338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT; Degioanni JJ; Calkins DS; Reschke MF; Bungo MW; Kutyna FA; Homick JL
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human centrifuge studies on the relative effectiveness of some antimotion sickness drugs.
    Wood CD; Graybiel A; McDonough R
    Aerosp Med; 1966 Feb; 37(2):187-90. PubMed ID: 5906041
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 19. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side effects of some antimotion sickness drugs as measured by psychomotor test and questionnaires.
    Kennedy RE; Wood CD; Graybiel A; McDonough RB
    Aerosp Med; 1966 Apr; 37(4):408-11. PubMed ID: 5954449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.